<DOC>
	<DOCNO>NCT02504372</DOCNO>
	<brief_summary>In study , participant Stage IB/II-IIIA non-small cell lung cancer ( NSCLC ) undergone surgical resection ( lobectomy pneumonectomy ) without adjuvant chemotherapy treat pembrolizumab placebo . The primary study hypothesis pembrolizumab provide improve disease-free survival ( DFS ) versus placebo .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) v Placebo Participants With Non-small Cell Lung Cancer After Resection With Without Standard Adjuvant Therapy ( MK-3475-091/KEYNOTE-091 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Pathological diagnosis NSCLC confirm surgery , histology Union International Cancer Control ( UICC ) v7 Stage IB T â‰¥ 4 cm , IIIIIA NSCLC complete surgical resection resection margin prove microscopically free disease ( R0 ) . Carcinoma situ present bronchial margin Available tumor sample obtain surgical resection program cell death ligand1 ( PDL1 ) Immunohistochemistry ( IHC ) expression assessment Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Adequate organ function perform within 10 day treatment initiation Female participant childbearing potential must negative urine serum pregnancy test screening ( within 72 hour first dose study medication ) . If urine test confirm negative , serum pregnancy test require . The serum pregnancy test must negative participant eligible Female participant childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study treatment Female participant breast feeding discontinue nurse prior first dose study medication 120 day last study treatment Male participant agree use adequate method contraception start first dose study treatment 120 day last dose study treatment Absence severe comorbidities opinion Investigator might hamper participation study and/or treatment administration No prior foresee neoadjuvant adjuvant radiotherapy and/or neoadjuvant chemotherapy Evidence disease clinical examination and/or baseline radiological assessment document contrast enhance chest/upper abdomen CT scan , brain CT/MRI clinical examination More 4 cycle adjuvant therapy Prior treatment antiprogrammed cell death ( antiPD ) 1 , antiPD ligand1/2 , antiCD137 , cytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) modulators Live vaccine within 30 day prior first dose study treatment Current participation treatment investigational agent use investigational device within 4 week first dose study treatment History Human Immunodeficiency Virus ( HIV ) ( know HIV 1/2 antibody positive ) . No known active Hepatitis B C Chronic use immunosuppressive agent and/or systemic corticosteroid use last 3 day prior first dose study treatment History interstitial lung disease ( noninfectious ) pneumonitis require oral IV steroid ( COPD exacerbation ) current pneumonitis Active autoimmune disease require systemic treatment past 2 year History hematologic primary solid tumor malignancy , unless remission least 5 year exception pT12 prostatic cancer Gleason score &lt; 6 , superficial bladder cancer , non melanomatous skin cancer carcinoma situ cervix Previous allogeneic tissue/solid organ transplant Active infection require therapy Surgery chemotherapyrelated toxicity resolve Grade 1 exception alopecia , fatigue , neuropathy lack appetite /nausea Pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose study treatment Participant eligible participant immediate family member ( e.g. , spouse , parent/legal guardian , sibling child ) investigational site Sponsor staff directly involve trial , unless prospective site Review Board approval give allow exception criterion specific participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL</keyword>
</DOC>